BioNTech SE Price, Chart & Factor Exposure
Free Data & Analytics AccessLatest earnings: November 3, 2026 results vs estimates
BioNTech SE Forecast
BioNTech SE short-term momentum is strongly negative (up over 0 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term SELL signal. The long-term trend is strongly negative (0 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term SELL signal. Based on 20-day realised volatility of 40.4% a year, a typical one-standard-deviation range is 84.06–94.20 over a week, 78.74–99.52 over a month and 53.13–125.13 over a year. (Signals as of 1 Nov 2026.)
BioNTech SE Price Chart
BioNTech SE Factors
YoY +28.8%
YoY +2.9%
YoY +93.5%
YoY −72.8%
YoY +162.3%
YoY −1.4%
YoY −31.1%
YoY +20.1%
YoY +21.3%
YoY +88.2%
YoY +52.8%
YoY −33.3%
YoY +8.0%
BioNTech SE fundamentals: income statement, balance sheet & cash flow
BioNTech SE reported revenue of $2.76bn and net income of -$1.09bn in FY2025, the year ended 31 December 2025 — revenue up 0.2% and net income down 64.0% on the prior year. Free cash flow was $269.8m. These figures are as reported in the filings, not restated: 9 fiscal years and 35 quarters of history, back to December 2017. 165 FINRA short-interest settlements are published alongside them, back to October 2019.
| USD billions | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
| Revenue | 2.76 | 2.75 | 3.82 | 17.31 | 18.98 |
| Cost of revenue | 0.62 | 0.54 | 0.60 | 3.00 | 2.91 |
| Gross profit | 2.14 | 2.21 | 3.22 | 14.32 | 16.07 |
| Research & development | 2.02 | 2.25 | 1.78 | 1.54 | 0.95 |
| Selling, general & admin. | — | 1.27 | — | 0.14 | — |
| Operating income | -0.62 | -1.31 | 0.69 | 12.64 | 15.28 |
| EBITDA | -0.63 | -0.37 | 1.38 | 13.10 | 15.00 |
| Interest expense | 0.01 | 0.01 | 0.01 | 0.02 | 0.01 |
| Pre-tax income | -1.01 | -0.68 | 1.19 | 12.95 | 15.05 |
| Income tax | 0.08 | -0.01 | 0.26 | 3.52 | 4.75 |
| Net income | -1.09 | -0.67 | 0.93 | 9.43 | 10.29 |
Download BioNTech SE fundamentals
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.BNTX.NASDAQ&statement=all&freq=a&format=csv&years=10
Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.
Research on BioNTech SE
Explore MacroFinance macro & markets research and analysis.
BioNTech SE Trading Strategies
58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to BioNTech SE; 28 of them are invested now. Strategies currently invested are listed first.
| Strategy | Style | Rebalance | Now in SPY, XLV | CAGR | Sharpe | Max DD |
|---|---|---|---|---|---|---|
| Tactical Permanent Portfolio | Conservative | Monthly | Premium · upgrade to view | |||
| Zakamulin and Giner's Optimal Trend Following | Moderate | Monthly | Premium · upgrade to view | |||
| Movement Capital's Composite Strategy | Moderate | Monthly | Premium · upgrade to view | |||
| Harry Browne's Permanent Portfolio | Conservative | Monthly | 25% | 7.0% | 0.96 | -17.2% |
| Keller and Van Putten's Flexible Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Ned Davis' Three Way Model | Moderate | Monthly | Premium · upgrade to view | |||
| 60_40 Benchmark | Moderate | Monthly | 60% | 8.2% | 0.93 | -29.5% |
| Dick Stoken's Active Combined Asset (ACA) - Monthly Trading | Moderate | Monthly | Premium · upgrade to view | |||
| PortfolioCharts' Golden Butterfly | Moderate | Monthly | 20% | 7.4% | 0.91 | -18.0% |
| US Cross-Asset Momentum | Moderate | Monthly | Premium · upgrade to view | |||
Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.
From creators
- P4 Demo Momentum by admin
- strategyx by admin
Statistical Distribution of Returns
PlusHow BioNTech SE’s returns are distributed — and how they change in a given market regime.
Regime filters
| Market/Macro | Indicator | Criteria | Value | And (for Between) | Action |
|---|
No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.
| Statistic | All periods | Matching |
|---|
About BioNTech SE (United States)
BioNTech SE is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).
Last updated: November 22, 2026
Frequently asked questions
What is BioNTech SE?
What is the latest BioNTech SE price?
Is BioNTech SE in an uptrend?
How volatile is BioNTech SE?
What factors affect BioNTech SE?
Which trading strategies trade BioNTech SE?
How are BioNTech SE returns analysed?
Where can I download free BioNTech SE historical data?
Free BioNTech SE historical data (last 10 years)
Browse or instantly download the last 10 years of BioNTech SE daily price history. A free account unlocks the full history, an Excel export with factors, and API access.
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.BNTX.NASDAQ&format=csv&years=10
| Date | Close |
|---|---|
| 2026-11-20 | 80.96 |
| 2026-11-19 | 81.38 |
| 2026-11-18 | 83.26 |
| 2026-11-17 | 84.86 |
| 2026-11-16 | 85.26 |
| 2026-11-13 | 85.6 |
| 2026-11-12 | 85.04 |
| 2026-11-11 | 87.65 |
| 2026-11-10 | 87.21 |
| 2026-11-09 | 87.51 |
About this stock
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.
See how this market's returns behaved when a factor was in a given state, for example when Momentum was strong or bond yields were above 4%, and compare that with all periods.
Reading the chart
- Each bar is a return bucket; its height is the share of periods that landed there.
- All periods: every return in the date range.
- Matching periods: only the periods where all your filters were true. If orange shifts right of the grey, returns were better in that regime.
- Each period's return is the return over the following day, week or month (set by Timeframe), measured from the day the factor was read, so there is no look-ahead.
Adding a filter
- Factor: grouped the same way as the Factors section on this page (Quantitative, Country, Sector, …). Locked factors are listed but greyed out.
- Criteria: greater (>), greater or equal (≥), equal (=), smaller or equal (≤), smaller (<) or between two values.
- Value: depends on the factor.
- Momentum and Trend are signals from −1 to +1, picked as −100 to +100 in steps of 25.
- Mean Reversion is a z-score of price against its 250-day mean, picked in σ from −3 to +3.
- Everything else is a number you type. The line under the box shows the latest reading and its typical range over the last 10 years.
Add several filters to combine conditions; a period must pass every one. Narrow the window with the From/To dates or the 1Y / 5Y / 10Y / MAX buttons; Clear resets filters and dates.
Return statistics
- Unfiltered vs Filtered: all periods vs matching periods.
- Average return, Std dev and Sharpe are annualised (252 days, 52 weeks, 12 months, 6 two-month periods, 4 quarters).
- Maximum drawdown compounds non-overlapping periods; in the Filtered column it assumes you held only while the condition was true.
- Min, 25th percentile, median, 75th percentile and max are per period, not annualised.